Adherence to Oral Anticancer Treatment Using Electronic Monitoring System

Centre Jean Perrin

Status: Completed

Conditions: Cancer

Treatments: Other: Evaluation of adherence to 3 oral anticancer treatment using a " Medication Event Monitoring System "

Study type: Interventional

Funder types: Other

Identifiers

NCT01058044

RCB 2009-A00244-53 (Other Identifier)

AU792

Details and patient eligibility

About

The purpose of this study is to describe adherence to 3 oral anticancer treatment: i) a chemotherapeutic regimen with capecitabine (alone or in association with lapatinib), ii) or sunitinib an tyrosine kinase inhibitor, iii) or an non-steroidal aromatase inhibitor. Moreover, this study is aimed at evaluating the feasibility to use a " Medication Event Monitoring System " (MEMS®) in order to assess adherence of an oral anticancer treatment delivered by dispensary pharmacy.

Enrollment: 33 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age > 18 years
• histologically proven malignant tumor
• documented decision of treatment with i) a chemotherapeutic regimen with capecitabine (alone or in association with lapatinib), ii) or sunitinib an tyrosine kinase inhibitor, iii) or an non-steroidal aromatase inhibitor
• ambulatory treated subject
• Subject who accept to use MEMS monitors to automatically compile their drug dosing histories
• Written informed consent

Exclusion criteria

• any severe concomitant wich makes it undesirable for the patient to participate in the study or which would jeopardize adherence with trial protocol
• patient who does not agreed to participate the program

Trial design

33 participants in 1 patient group

adherence assessment group

Experimental group

Description:

evaluation of adherence using MEMS

Treatment:

Other: Evaluation of adherence to 3 oral anticancer treatment using a " Medication Event Monitoring System "